Bluebird bio’s experimental therapy for the genetic blood disorder beta-thalassemia major is working just as the biotech planned, using a single dose to wean two more patients off of the chronic transfusions required to treat the disease.

…read more

Source: Bluebird posts more promising results for its rare disease therapy


0 No comments